Advanced Cancer Clinical Trial
Official title:
Efficacy of Self-education Program for Advanced Care Planning: A Randomized Controlled Trial
Verified date | October 2018 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study verifies efficacy of Self-education program for advanced care planning. Half of participants will receive a book and videos about advanced care planning while the other half will receive a book and videos about pain control for cancer patients.
Status | Completed |
Enrollment | 238 |
Est. completion date | February 28, 2018 |
Est. primary completion date | February 21, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Subject 20 years old and more - Subject who understands the purpose of the study and signs with informed consent form - Subject with advanced cancer - Subject who knows he/she is diagnosed with advanced cancer Exclusion Criteria: - Inability to speak, understand, or write Korean - Inability to understand the contents of the provided materials due to poor eyesight and hearing - Medical conditions that would limit adherence to participation of the clinical trial (as confirmed by their referring physician; e.g. dyspnea, depression and other mental disorders) |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital | Asan Medical Center, Daegu Fatima Hospital, South Korea, Ewha Womans University Mokdong Hospital, Gangneung Asan Hospital, Keimyung University Dongsan Medical Center, Korea University Anam Hospital, National Clinical Research Coordination Center, Seoul, Korea, National Evidence-Based Healthcare Collaborating Agency, National Institute of Health, Korea, Pohang Semyeong Christianity Hospital, Ulsan University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in End-of-life Care Preference | Comparison the result of End-of-life Care Preference questionnaire | Baseline, within 1 week, 7 weeks | |
Secondary | Changes in Hospital Anxiety and Depression Scale | Comparison the result of Hospital Anxiety and Depression Scale | Baseline, 7 weeks | |
Secondary | Changes in Decision Conflict | Comparison the result of decision conflict questionnaire | Baseline, 7 weeks | |
Secondary | Changes in EOL care Discussion and Documentation | Comparison the result of EOL care Discussion and Documentation questionnaire | Baseline, 7 weeks | |
Secondary | Changes in Satisfaction on educational materials | Comparison Satisfaction on educational materials questionnaire | Baseline, 7 weeks | |
Secondary | Changes in Decisional Role Preference | Comparison the result of decisional role preference questionnaire | Baseline, 7 weeks | |
Secondary | Changes in Knowledge of CPR | Comparison the result of knowledge of CPR questionnaire | Baseline, 7 weeks | |
Secondary | Intention to document advance care planning | Comparison the result of advance care planning questionnaire | Baseline, 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A |